Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer |
Ban, Hee-Jung
(Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School)
Oh, In-Jae (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) Kim, Kyu-Sik (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) Ju, Jin-Yung (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School) Kwon, Yong-Soo (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School) Kim, Yu-Il (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School) Lim, Sung-Chul (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School) Kim, Young-Chul (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) |
1 | Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29 DOI ScienceOn |
2 | Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a cancer research campaign trial. Br J Cancer 1989;59:578-83 DOI PUBMED ScienceOn |
3 | Eckardt JR, Ardizzoni A, von Pawel J, Fields S. Pooled analysis of topotecan in the second-line treatment of patients with sensitive small cell lung cancer. Proc Am Soc Clin Oncol 1997;15:1624a DOI |
4 | von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67 PUBMED |
5 | Jeong JH, Kim SH, Choi HJ, Shin SJ, Cho BC, Kuen IC, et al. Phase II trial of belotecan in patients with relapsed small-cell lung cancer after irinotecan-containing chemotherapy. Korean J Med 2007;73:S155 |
6 | Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 2000;922:324-5 PUBMED |
7 | Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96 DOI ScienceOn |
8 | Rocha Lima CM, Chiappori A. Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung Cancer 2003;40:229-36 DOI ScienceOn |
9 | Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123:259S-271S DOI PUBMED ScienceOn |
10 | Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The european organization for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J Clin Oncol 1997;15:2090-6 DOI PUBMED |